Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02320032 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
A Phase 1 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT02320032 is a Phase 1 study that has completed, run by Alkermes. The registered enrollment target is 140 participants.
The verdict
NCT02320032, a Phase 1 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.
Interventions
- DRUG Aripiprazole Lauroxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02320032
The ClinicalTrials.gov registry entry for NCT02320032 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole Lauroxil is the first listed.
NCT02320032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02320032 about?
NCT02320032 is a clinical study titled "An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia". This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.
What is the current status of trial NCT02320032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2014-12. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02320032?
The interventions under investigation include: Aripiprazole Lauroxil (DRUG).
Who is sponsoring clinical trial NCT02320032?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.